Laura Prendergast
Stock Analyst at Stifel Nicolaus
(4.74)
# 674
Out of 4,704 analysts
80
Total ratings
56.9%
Success rate
38.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Laura Prendergast
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintained: Buy | $215 | $210.02 | +2.37% | 21 | Aug 27, 2026 | |
| STRO Sutro Biopharma | Maintained: Buy | $48 | $20.07 | +139.16% | 2 | Aug 17, 2026 | |
| TNGX Tango Therapeutics | Maintained: Buy | $40 | $22.52 | +77.62% | 10 | Aug 17, 2026 | |
| FHTX Foghorn Therapeutics | Maintained: Buy | $12 | $4.92 | +143.90% | 7 | Aug 17, 2026 | |
| ERAS Erasca | Maintained: Buy | $30 | $16.19 | +85.30% | 12 | Aug 17, 2026 | |
| BDTX Black Diamond Therapeutics | Maintained: Buy | $8 | $2.12 | +277.36% | 7 | Aug 6, 2026 | |
| ORIC ORIC Pharmaceuticals | Maintained: Buy | $14 | $12.86 | +8.86% | 2 | Aug 4, 2026 | |
| COGT Cogent Biosciences | Maintained: Buy | $45 | $34.76 | +29.46% | 9 | Jun 15, 2026 | |
| BBOT BridgeBio Oncology Therapeutics | Maintained: Buy | $23 | $8.98 | +156.12% | 4 | May 13, 2026 | |
| OLMA Olema Pharmaceuticals | Initiated Coverage: Buy | $48 | $10.75 | +346.51% | 1 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $11.78 | n/a | 3 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 | $9.00 | n/a | 1 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $16 | $2.92 | n/a | 1 | Aug 14, 2024 |
Revolution Medicines
Aug 27, 2026
Maintained: Buy
Price Target: $215
Current: $210.02
Upside: +2.37%
Sutro Biopharma
Aug 17, 2026
Maintained: Buy
Price Target: $48
Current: $20.07
Upside: +139.16%
Tango Therapeutics
Aug 17, 2026
Maintained: Buy
Price Target: $40
Current: $22.52
Upside: +77.62%
Foghorn Therapeutics
Aug 17, 2026
Maintained: Buy
Price Target: $12
Current: $4.92
Upside: +143.90%
Erasca
Aug 17, 2026
Maintained: Buy
Price Target: $30
Current: $16.19
Upside: +85.30%
Black Diamond Therapeutics
Aug 6, 2026
Maintained: Buy
Price Target: $8
Current: $2.12
Upside: +277.36%
ORIC Pharmaceuticals
Aug 4, 2026
Maintained: Buy
Price Target: $14
Current: $12.86
Upside: +8.86%
Cogent Biosciences
Jun 15, 2026
Maintained: Buy
Price Target: $45
Current: $34.76
Upside: +29.46%
BridgeBio Oncology Therapeutics
May 13, 2026
Maintained: Buy
Price Target: $23
Current: $8.98
Upside: +156.12%
Olema Pharmaceuticals
Feb 11, 2026
Initiated Coverage: Buy
Price Target: $48
Current: $10.75
Upside: +346.51%
Jul 29, 2025
Maintained: Buy
Price Target: $12
Current: $11.78
Upside: n/a
Feb 13, 2025
Maintained: Buy
Price Target: $4
Current: $9.00
Upside: n/a
Aug 14, 2024
Upgraded: Buy
Price Target: $16
Current: $2.92
Upside: n/a